The respiratory system, whose pathophysiology is studied and treated in the corresponding therapeutic area, is, together with the cardiovascular system to which it is closely connected, the “engine” of our body.
Respiratory diseases come second only to cardiovascular disorders in terms of mortality, incidence and costs. In Europe, the primary causes of respiratory death include pneumonia and chronic obstructive pulmonary disease (COPD). Worldwide, hundreds of millions of people suffer every day from chronic respiratory diseases. According to the global estimates of the World Health Organization (WHO), 300 million individuals suffer from asthma, 210 million people have COPD, and a great many others suffer from allergic rhinitis and other, often under-diagnosed, respiratory conditions.
Climate change is the likely culprit of a number of negative effects on our health, as described by the WHO. In Europe and elsewhere, mortality from chronic respiratory and lung disease is expected to increase in the future.
In addition to its mucolytic products, the IBSA range also includes other products containing hyaluronic acid that are indicated as adjuvants in the treatment of a number of respiratory conditions.